% ‐39% 4.4% 81% 14% ‐8.5% ‐20% 30% 64% ‐3.1% 19% ‐16% %YoY ‐8.5% 66% NA 17% ‐67% 13% F C h h f Finan (Bt m Cash ST in Trad Inven Othe Curre Spec Netw Intan Defe Othe Tota
TFRS-15) Total asset was Bt283,593mn in 3Q19, decreased by 2.4% from 4Q18 as spectrum licenses had been amortized. However, some of the effect was negated by an increase in cash. Current liability
comprised of cash and short-term investment amounted to THB 4,035 million, with total liabilities of THB 2,959 million and total equities of THB 9,708 million. In this regard, the company’s financial position
transaction Currently, the Company encounters the situation of the lack of financial liquidity and the cash flow for the business operation, as the Company has continuous accumulated loss. Thus, the Company
02-634-0135 www.interpharma.co.th 4. MP Financial Statement Balance Sheet (Unit : Baht) 2017 Audited Statement 2018 Audited Statement 2019 Audited Statement Assets Current Assets Cash and cash
8.1% from Dec-20 due to an increase in retained earnings. Cash flow In FY21, Cash flow from operation reported Bt86,634mn increasing 1.2% YoY following EBITDA improvement. Total investing cash flow was
THB 12,931 million which comprised of cash and short- term investment amounting to THB 3,311 million, with total liabilities of THB 3,283 million and total equities of THB 9,648 million. In this regard
time or several times within three months from the date on which the Board of Directors of the Company has the resolution. A purpose is to help the Company to have enough cash flow for a business
within three months from the date on which the Board of Directors of the Company has the resolution. A purpose is to help the Company to have enough cash flow for a business operation and increase in the